Schering-Plough's Saphris better than Zyprexa in schizophrenia study
This article was originally published in Scrip
Schering-Plough's atypical antipsychotic candidate Saphris (asenapine maleate) has met the primary endpoint of a year-long extension study, showing it to be more effective than Lilly's Zyprexa (olanzapine) in reducing the negative symptoms of schizophrenia.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.